NHS England Unveils Rapid Test for Brain Tumors
Surgeons can now identify a brain tumor’s genetic makeup before a patient even leaves the operating table, cutting what used to be an eight-week wait for diagnosis down to about two hours. The Brain Tumor Research Center of Excellence at the University of Nottingham built the tool, and the NHS has already begun putting it to use.
Genomic analysis sits at the core of the gamechanging technology. Small tissue samples travel from the tumor site to a pathology lab, where a sequencing device roughly the size of a shoebox, built by Oxford Nanopore, threads strands of DNA through microscopic pores. That process maps the tumor’s genome directly, sidestepping the traditional method of examining tissue under a microscope, and reveals the tumor’s exact type with far more precision than older techniques allowed.
Speed matters enormously here, particularly for the most aggressive tumor types. Glioblastoma, the most common malignant brain tumor in adults, still carries a median survival of just 12 to 18 months even after surgery, chemotherapy, and radiation, and most patients eventually see their tumor return.
Part of what makes it so difficult to treat is the blood-brain barrier, a protective layer that blocks many cancer drugs from ever reaching the tumor, along with the tendency of glioblastoma cells to vary widely even within a single patient, undermining treatments designed around a single genetic target.
Researchers have made real progress on that front in recent years. More than 200 companies are now developing experimental glioblastoma therapies, spanning targeted drugs, immune-based treatments, and new ways of delivering medication past the blood-brain barrier using nanoparticles and other engineered carriers.
None represents a single breakthrough cure, but clinicians increasingly describe the field’s progress as incremental gains stacking up across surgery, radiotherapy, and molecular treatment rather than one decisive advance.
A fast, reliable way to genetically profile a tumor during surgery fits squarely into that pattern, giving doctors a head-start on matching patients to the treatments most likely to help them. Primary brain tumors kill more children and adults under 40 in the UK than any other type of cancer, and faster diagnosis means treatment can begin sooner, potentially opening the door to clinical trials that patients might otherwise miss entirely.
NHS medical director Frankie Swords called the tool a major step forward for patients, saying it has the potential to reshape how brain tumors get diagnosed altogether.
Stuart Smith, a consultant neurosurgeon at Nottingham University Hospitals NHS Trust and co-lead of the research center behind the test, said he takes real pride in helping build a tool that recovers precious time for patients who may have little of it to spare. Having detailed genetic information available the moment surgical decisions are being made, he said, changes the entire calculation doctors face in the operating room.
Five specialist centers will pilot the test first: Nottingham, University Hospitals Birmingham, Great Ormond Street, King’s College Hospital, and Newcastle. Bristol, Oxford, Leeds, and Manchester are lined up to follow once the initial rollout is complete.
As diagnostic tools for brain tumors get better, patients could have a real chance of benefiting from the treatments being developed by biotech companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) once treatment is started early.
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer
Surgeons can now identify a brain tumor’s genetic makeup before a patient even leaves the operating table, cutting what used to be an eight-week wait for diagnosis down to about two hours. The Brain Tumor Research Center of Excellence at the University of Nottingham built the tool, and the NHS has already begun putting it to use.
Genomic analysis sits at the core of the gamechanging technology. Small tissue samples travel from the tumor site to a pathology lab, where a sequencing device roughly the size of a shoebox, built by Oxford Nanopore, threads strands of DNA through microscopic pores. That process maps the tumor’s genome directly, sidestepping the traditional method of examining tissue under a microscope, and reveals the tumor’s exact type with far more precision than older techniques allowed.
Speed matters enormously here, particularly for the most aggressive tumor types. Glioblastoma, the most common malignant brain tumor in adults, still carries a median survival of just 12 to 18 months even after surgery, chemotherapy, and radiation, and most patients eventually see their tumor return.
Part of what makes it so difficult to treat is the blood-brain barrier, a protective layer that blocks many cancer drugs from ever reaching the tumor, along with the tendency of glioblastoma cells to vary widely even within a single patient, undermining treatments designed around a single genetic target.
Researchers have made real progress on that front in recent years. More than 200 companies are now developing experimental glioblastoma therapies, spanning targeted drugs, immune-based treatments, and new ways of delivering medication past the blood-brain barrier using nanoparticles and other engineered carriers.
None represents a single breakthrough cure, but clinicians increasingly describe the field’s progress as incremental gains stacking up across surgery, radiotherapy, and molecular treatment rather than one decisive advance.
A fast, reliable way to genetically profile a tumor during surgery fits squarely into that pattern, giving doctors a head-start on matching patients to the treatments most likely to help them. Primary brain tumors kill more children and adults under 40 in the UK than any other type of cancer, and faster diagnosis means treatment can begin sooner, potentially opening the door to clinical trials that patients might otherwise miss entirely.
NHS medical director Frankie Swords called the tool a major step forward for patients, saying it has the potential to reshape how brain tumors get diagnosed altogether.
Stuart Smith, a consultant neurosurgeon at Nottingham University Hospitals NHS Trust and co-lead of the research center behind the test, said he takes real pride in helping build a tool that recovers precious time for patients who may have little of it to spare. Having detailed genetic information available the moment surgical decisions are being made, he said, changes the entire calculation doctors face in the operating room.
Five specialist centers will pilot the test first: Nottingham, University Hospitals Birmingham, Great Ormond Street, King’s College Hospital, and Newcastle. Bristol, Oxford, Leeds, and Manchester are lined up to follow once the initial rollout is complete.
As diagnostic tools for brain tumors get better, patients could have a real chance of benefiting from the treatments being developed by biotech companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) once treatment is started early.
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer
